Danaher (DHR) expects FY25 adj. EPS at the upper-end of the previously announced USD 7.70-7.80 guidance range
Importance
Level 1
- Q4 revenue growth seen at the high-end of the announced range.
- CEO "We were especially pleased with continued strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in the fourth quarter."
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#DANAHER CORP#DHR.US#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#LIFE SCIENCES TOOLS & SERVICES#METALS & MINING#LIFE SCIENCES TOOLS & SERVICES (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DHR#DXY#US EQUITIES